Rhabdomyosarcoma - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 147 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2016, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 5, 2 and 1 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 3 and 1 molecules, respectively for Rhabdomyosarcoma.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Rhabdomyosarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Rhabdomyosarcoma - Overview 9
Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 10
Rhabdomyosarcoma - Therapeutics under Development by Companies 11
Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 12
Rhabdomyosarcoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Rhabdomyosarcoma - Products under Development by Companies 15
Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 16
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 17
Bellicum Pharmaceuticals, Inc. 17
Boehringer Ingelheim GmbH 18
Celgene Corporation 19
EpiZyme, Inc. 20
Exelixis, Inc. 21
Immunomedics, Inc. 22
Iproteos S.L. 23
Merrimack Pharmaceuticals, Inc. 24
Morphotek, Inc. 25
Novartis AG 26
Noxxon Pharma AG 27
Pfizer Inc. 28
Shionogi & Co., Ltd. 29
Rhabdomyosarcoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
afatinib dimaleate - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
axitinib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
cabozantinib s-malate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Cellular Immunotherapy for Oncology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
celyvir - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
crizotinib - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
everolimus - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Hex-hR1 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
irinotecan hydrochloride - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
MAL-3101 - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
NOXS-93 - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
ontuxizumab - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
paclitaxel albumin bound - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
pazopanib hydrochloride - Drug Profile 127
Product Description 127
Mechanism Of Action 127
R&D Progress 127
S-588410 - Drug Profile 134
Product Description 134
Mechanism Of Action 134
R&D Progress 134
Synthetic Peptides for Rhabdomyosarcoma - Drug Profile 136
Product Description 136
Mechanism Of Action 136
R&D Progress 136
tazemetostat - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
Rhabdomyosarcoma - Dormant Projects 144
Rhabdomyosarcoma - Discontinued Products 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 146
Disclaimer 147

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H2 2016 9
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 17
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 18
Rhabdomyosarcoma - Pipeline by Celgene Corporation, H2 2016 19
Rhabdomyosarcoma - Pipeline by EpiZyme, Inc., H2 2016 20
Rhabdomyosarcoma - Pipeline by Exelixis, Inc., H2 2016 21
Rhabdomyosarcoma - Pipeline by Immunomedics, Inc., H2 2016 22
Rhabdomyosarcoma - Pipeline by Iproteos S.L., H2 2016 23
Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 24
Rhabdomyosarcoma - Pipeline by Morphotek, Inc., H2 2016 25
Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2016 26
Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H2 2016 27
Rhabdomyosarcoma - Pipeline by Pfizer Inc., H2 2016 28
Rhabdomyosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Rhabdomyosarcoma - Dormant Projects, H2 2016 144
Rhabdomyosarcoma - Discontinued Products, H2 2016 145